Back to top
more

Eli Lilly (LLY)

(Real Time Quote from BATS)

$811.50 USD

811.50
861,539

-7.43 (-0.91%)

Updated Nov 4, 2024 10:26 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (60 out of 250)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Lilly's Study on Higher Doses of Trulicity Meets Endpoint

by Zacks Equity Research

Lilly's (LLY) phase III study evaluating higher doses of Trulicity meets primary and secondary efficacy endpoints.

Axsome Initiates Phase III Study on Depression Candidate

by Zacks Equity Research

Axsome (AXSM) initiates phase III GEMINI study of AXS-05 for the treatment of major depressive disorder.

Neena Mishra headshot

Why These Innovative Biotech ETFs Are Soaring

by Neena Mishra

Strong M&A activity has sent shares of many small, innovative biotech companies surging

Allergan's Botox Wins FDA Nod for Upper Limb Spasticity in Kids

by Zacks Equity Research

Allergan's (AGN) Botox gets FDA approval for the 10th therapeutic indication, upper limb spasticity in pediatric patients, in the age group of 2 to 17 years.

Allergan Up As Analyst Statement Sparks Business Split Rumors

by Zacks Equity Research

Allergan's (AGN) shares up following a conference call with one of the company's executives, which led an analyst to believe that a split of the company's business is in the cards.

Pfizer to Buy Array BioPharma, Broaden Cancer Portfolio

by Zacks Equity Research

Pfizer (PFE) offers $48 per share to buy Array BioPharma and strengthen its cancer portfolio.

Novo Nordisk's Victoza Gets FDA Nod for Pediatric Patients

by Zacks Equity Research

Novo Nordisk's (NVO) Victoza gets FDA approval for the treatment of pediatric patients aged 10 years or older with type II diabetes.

Are You Looking for a High-Growth Dividend Stock? Eli Lilly (LLY) Could Be a Great Choice

by Zacks Equity Research

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Eli Lilly (LLY) have what it takes? Let's find out.

Kinjel Shah headshot

Pharma Stock Roundup: MRK Buys Small Cancer Biotech, RHHBY, MRK Drugs Get FDA Nod

by Kinjel Shah

Key developments of the week include Merck's (MRK) deal to buy Tilos Therapeutics and FDA approval for Roche's (RHHBY) polatuzumab vedotin and Merck's Keytruda.

NuCana's Biliary Tract Cancer Candidate Gets Orphan Drug Tag

by Zacks Equity Research

The FDA confers an orphan drug designation on NuCana's (NCNA) pipeline candidate, Acelarin, for treating patients with biliary tract cancer

Pfizer's (PFE) Xeljanz Effective As Monotherapy in RA Study

by Zacks Equity Research

Pfizer's (PFE) study on JAK inhibitor Xeljanz XR demonstrates the efficacy of the medicine when used as a monotherapy without methotrexate.

Galapagos Ends Enrollment in Osteoarthritis Study Before Time

by Zacks Equity Research

Galapagos (GLPG) closes enrollment in the phase II study on GLPG1972/S201086 for the treatment of patients with osteoarthritis prior to the stipulated date.

Kinjel Shah headshot

Boost Your Portfolio's Health With These 3 Big Drug Stocks

by Kinjel Shah

The large-cap pharma industry is doing well in 2019. Here are three stocks from the space that investors may consider betting on.

The Zacks Analyst Blog Highlights: Oracle, Eli Lilly, Mondelez, Walgreens and Southwest

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Oracle, Eli Lilly, Mondelez, Walgreens and Southwest

Lilly Announces Tradjenta Cardiovascular Outcome Study Data

by Zacks Equity Research

Tradjenta leads to fewer events of hypoglycemia and modest weight reduction in type II diabetes patients compared to Sanofi's Amaryl.

Merck (MRK) to Buy Private Biotech Tilos for Up to $773M

by Zacks Equity Research

Merck (MRK) set to buy private preclinical biotech Tilos Therapeutics in a deal that could be worth up to $773 million

The Zacks Analyst Blog Highlights: Bristol Myers, Merck, Roche, Lilly and AstraZeneca

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Bristol Myers, Merck, Roche, Lilly and AstraZeneca

Lilly (LLY) Presents Data From Diabetes Studies at ADA Meet

by Zacks Equity Research

Lilly (LLY) presents additional data from studies on investigational diabetes products ultra-rapid-acting lispro and tirzepatide and outcomes study (REWIND) on Trulicity at ADA.

Mark Vickery headshot

Top Analyst Reports for Oracle, Eli Lilly & Mondelez

by Mark Vickery

Today's Research Daily features new research reports on 16 major stocks, including Oracle (ORCL), Eli Lilly (LLY) and Mondelez (MDLZ).

Kinjel Shah headshot

Pharma Stock Roundup: ASCO Update, FDA Nod for LLY's Emgality for Cluster Headache

by Kinjel Shah

Pharma bigwigs present data from cancer studies at ASCO. Lilly's (LLY) CGRP Emgality gets FDA approval for episodic cluster headache in adults.

Incyte Begins Phase III Study for Treatment of Duct Cancer

by Zacks Equity Research

Incyte (INCY) begins first phase III study of pemigatinib as a first-line therapy for patients with metastatic or surgically unresectable cholangiocarcinoma.

Lilly's Emgality Gets FDA Approval for Cluster Headache

by Zacks Equity Research

Lilly's (LLY) CGRP antibody, Emgality, becomes the first and only medicine approved to treat episodic cluster headache in adults.

Celldex Presents Data From CDX-3379 Study at ASCO, Stock Down

by Zacks Equity Research

Celldex (CLDX) presents updated data on CDX-3379 and Erbitux combination regimen, which supports further development in biomarker selected patient population.

Neena Mishra headshot

Why Cancer-Fighting Stocks & ETFs Are Soaring

by Neena Mishra

The cancer immunotherapy ETF is soaring today as some of its holdings presented very promising results at the ASCO conference. Find out more on the podcast.

Merck's Keytruda Improves 5-Year Survival in Lung Cancer

by Zacks Equity Research

Merck (MRK) presents longest follow-up data for Keytruda in advance lung cancer at ASCO 2019. The five-year overall survival rates in the Keytruda arm are better than historical rates